CoChat

Abcd2 Is a Strong Modifier of the Metabolic Impairments in Peritoneal Macrophages of Abcd1-Deficient Mice

Open access

The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index; 19 of the 30 sources its claims cite were checked for support.

Abstract

The inherited peroxisomal disorder X-linked adrenoleukodystrophy (X-ALD), associated with neurodegeneration and inflammatory cerebral demyelination, is caused by mutations in the ABCD1 gene encoding the peroxisomal ATP-binding cassette (ABC) transporter ABCD1 (ALDP). ABCD1 transports CoA-esters of very long-chain fatty acids (VLCFA) into peroxisomes for degradation by β-oxidation; thus, ABCD1 deficiency results in VLCFA accumulation. The closest homologue, ABCD2 (ALDRP), when overexpressed, compensates for ABCD1 deficiency in X-ALD fibroblasts and in Abcd1-deficient mice. Microglia/macrophages have emerged as important players in the progression of neuroinflammation. Human monocytes, lacking significant expression of ABCD2, display severely impaired VLCFA metabolism in X-ALD. Here, we used thioglycollate-elicited primary mouse peritoneal macrophages (MPMΦ) from Abcd1 and Abcd2 single- and double-deficient mice to establish how these mutations affect VLCFA metabolism. By quantitative RT-PCR, Abcd2 mRNA was about half as abundant as Abcd1 mRNA in wild-type and similarly abundant in Abcd1-deficient MPMΦ. VLCFA (C26∶0) accumulated about twofold in Abcd1-deficient MPMΦ compared with wild-type controls, as measured by gas chromatography-mass spectrometry. In Abcd2-deficient macrophages VLCFA levels were normal. However, upon Abcd1/Abcd2 double-deficiency, VLCFA accumulation was markedly increased (sixfold) compared with Abcd1-deficient MPMΦ. Elovl1 mRNA, encoding the rate-limiting enzyme for elongation of VLCFA, was equally abundant across all genotypes. Peroxisomal β-oxidation of C26∶0 amounted to 62% of wild-type activity in Abcd1-deficient MPMΦ and was significantly more impaired (29% residual activity) upon Abcd1/Abcd2 double-deficiency. Single Abcd2 deficiency did not significantly compromise β-oxidation of C26∶0. Thus, the striking accumulation of VLCFA in double-deficient MPMΦ compared with single Abcd1 deficiency was due to the loss of ABCD2-mediated, compensatory transport of VLCFA into peroxisomes. We propose that moderate endogenous expression of Abcd2 in Abcd1-deficient murine macrophages prevents the severe metabolic phenotype observed in human X-ALD monocytes, which lack appreciable expression of ABCD2. This supports upregulation of ABCD2 as a therapeutic concept in X-ALD.

Overview

CoChat Summary

TL;DR

In Abcd1-deficient mouse peritoneal macrophages, endogenous Abcd2 expression at about half the level of Abcd1 substantially compensates for loss of ABCD1, limiting VLCFA accumulation and preserving peroxisomal β-oxidation. Combined Abcd1/Abcd2 deficiency causes a much more severe metabolic phenotype, supporting ABCD2 upregulation as a therapeutic concept in X-linked adrenoleukodystrophy.

Key findings

  • In wild-type mouse peritoneal macrophages, Abcd2 mRNA was present at 58% of Abcd1 mRNA; Abcd2 mRNA levels were not significantly changed in Abcd1-deficient macrophages.
  • C26:0 accumulated about twofold in Abcd1-deficient macrophages versus wild-type, but was normal in Abcd2-deficient macrophages; Abcd1/Abcd2 double deficiency increased C26:0 accumulation sixfold compared with Abcd1 deficiency alone, or about twelvefold versus wild-type.
  • Peroxisomal β-oxidation of C26:0 was 62% of wild-type activity in Abcd1-deficient macrophages and fell to 29% residual activity in Abcd1/Abcd2 double-deficient macrophages; single Abcd2 deficiency did not significantly impair C26:0 β-oxidation.
  • Elovl1 mRNA was equally abundant across all genotypes, and C16:0 β-oxidation was similar across genotypes, suggesting the double-deficiency phenotype was due mainly to loss of ABCD2-mediated compensatory VLCFA transport into peroxisomes.

Methods

  • Abcd2-deficient mice were generated by targeted inactivation and crossed with Abcd1-deficient mice on the C57BL/6J background; adult 3–6-month-old male mice were used to isolate thioglycollate-elicited primary mouse peritoneal macrophages.
  • mRNA levels for Abcd1, Abcd2, and Elovl1 were measured by quantitative RT-PCR and normalized to Hprt; VLCFA species C26:0, C24:0, C22:0, and C16:0 were measured by GC-MS.
  • Peroxisomal β-oxidation was assayed using 1-14C-labelled C26:0 and C16:0; statistical analyses used t-tests or one-way ANOVA with post-hoc tests, with significance at p<0.05.

Limitations

  • The authors state that the findings cannot be directly translated to human perivascular or parenchymal macrophages or activated microglia in X-ALD brain lesions, and that species differences may contribute to the lack of cerebral inflammatory phenotype in mouse models.
  • The authors note they cannot exclude altered ELOVL1 enzymatic activity or substrate availability, although they consider a major contribution unlikely given the impaired VLCFA degradation.
  • Evident from the text: many experiments used n=3, only male mice were studied, and thioglycollate-elicited peritoneal macrophages may differ from resident macrophages or microglia; the paper also notes possible eosinophil contamination in such preparations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0108655

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Strategy and molecular evidence for targeted inactivation of the Abcd2 gene. (A) Structure of the 5′ region of the Abcd2 gene, the targeting construct and the disrupted gene. Exons (Ex) 1–3 are depicted as boxes with the protein coding region in gray. After homologous recombination, 1.24 kb of the Abcd2 gene, including the transcription and translation start sites and most of exon 1, is replaced by the neomycin resistance gene cassette (Neo) of the targeting construct. Positions of the PCR primers (P1, P2) and the Southern blot probe (****) used in genotyping to detect homologous recombination are indicated. Restriction sites used for cloning or analysis are marked: H, HindIII; N, NdeI; Not, NotI; S, ScaI; Sp, SphI and X, XhoI. (B) Southern blot analysis of ScaI-digested DNA from Abcd2 −/−, Abcd2 +/+ and Abcd2 +/− mice. Chemiluminescent detection of a digoxygenin-labelled probe from the 5′ flanking DNA verified homologous recombination based on deletion of a ScaI-site in exon 1 of Abcd2 resulting in 3.9-kb and 4.4-kb fragments from the wild-type (WT) and knock-out (KO) alleles, respectively. (C) Northern blot analysis of mRNA from brain and skeletal muscle of adult Abcd2 −/− and Abcd2 +/+ mice. A 32P-labelled Abcd2 cDNA probe hybridized to the major 4.2 kb Abcd2 mRNA and minor (5.5 and 2.8 kb) variants in both tissues of wild-type mice, but not in Abcd2 −/− mice. As a loading control, the blot was re-probed with β-actin cDNA, which in skeletal muscle detects a shorter, more abundant mRNA than in brain. (D) Reverse transcription-coupled PCR analysis of Abcd2 mRNA expression in primary peritoneal macrophages from two Abcd2 +/+ and two Abcd2 −/− mice. Abcd2-specific primers amplified the expected 1,051-bp product in Abcd2 +/+ but not in Abcd2 −/− macrophages. As a positive control, amplification of Iba1 cDNA (310-bp fragment) was confirmed in all samples.
Figure 1 Strategy and molecular evidence for targeted inactivation of the Abcd2 gene. (A) Structure of the 5′ region of the Abcd2 gene, the targeting construct and the disrupted gene. Exons (Ex) 1–3 are depicted as boxes with the protein coding region in gray. After homologous recombination, 1.24 kb of the Abcd2 gene, including the transcription and translation start sites and most of exon 1, is replaced by the neomycin resistance gene cassette (Neo) of the targeting construct. Positions of the PCR primers (P1, P2) and the Southern blot probe (****) used in genotyping to detect homologous recombination are indicated. Restriction sites used for cloning or analysis are marked: H, HindIII; N, NdeI; Not, NotI; S, ScaI; Sp, SphI and X, XhoI. (B) Southern blot analysis of ScaI-digested DNA from Abcd2 −/−, Abcd2 +/+ and Abcd2 +/− mice. Chemiluminescent detection of a digoxygenin-labelled probe from the 5′ flanking DNA verified homologous recombination based on deletion of a ScaI-site in exon 1 of Abcd2 resulting in 3.9-kb and 4.4-kb fragments from the wild-type (WT) and knock-out (KO) alleles, respectively. (C) Northern blot analysis of mRNA from brain and skeletal muscle of adult Abcd2 −/− and Abcd2 +/+ mice. A 32P-labelled Abcd2 cDNA probe hybridized to the major 4.2 kb Abcd2 mRNA and minor (5.5 and 2.8 kb) variants in both tissues of wild-type mice, but not in Abcd2 −/− mice. As a loading control, the blot was re-probed with β-actin cDNA, which in skeletal muscle detects a shorter, more abundant mRNA than in brain. (D) Reverse transcription-coupled PCR analysis of Abcd2 mRNA expression in primary peritoneal macrophages from two Abcd2 +/+ and two Abcd2 −/− mice. Abcd2-specific primers amplified the expected 1,051-bp product in Abcd2 +/+ but not in Abcd2 −/− macrophages. As a positive control, amplification of Iba1 cDNA (310-bp fragment) was confirmed in all samples.CC BY · PubMed Central
Figure 2 Endogenous Abcd1 and Abcd2 mRNA levels in peritoneal macrophages of wild-type and Abcd1-deficient mice. (A) The Abcd1 and Abcd2 mRNA copy numbers in C57BL/6J wild-type MPMΦ were determined by qRT-PCR. (B) Comparison of Abcd2 mRNA levels in wild-type (WT) and Abcd1-deficient (KO) MPMΦ. The numbers of samples (n) are indicated below the graphs. The graphs indicate mean values ± SD after normalization to the level of Hprt mRNA in each sample; n.s., no statistically significant difference.
Figure 2 Endogenous Abcd1 and Abcd2 mRNA levels in peritoneal macrophages of wild-type and Abcd1-deficient mice. (A) The Abcd1 and Abcd2 mRNA copy numbers in C57BL/6J wild-type MPMΦ were determined by qRT-PCR. (B) Comparison of Abcd2 mRNA levels in wild-type (WT) and Abcd1-deficient (KO) MPMΦ. The numbers of samples (n) are indicated below the graphs. The graphs indicate mean values ± SD after normalization to the level of Hprt mRNA in each sample; n.s., no statistically significant difference.CC BY · PubMed Central
Figure 3 VLCFA levels in wild-type, Abcd1 and Abcd2 single-deficient and Abcd1/Abcd2 double-deficient mouse peritoneal macrophages. The concentrations of the VLCFA species C26∶0, C24∶0 and C22∶0 and the LCFA C16∶0 were determined by GC-MS. The relative amounts of fatty acids, expressed as ratios: (A) C26∶0/C22∶0; (B) C26∶0/C16∶0; (C) C24∶0/C22∶0 and (D), C22∶0/C16∶0 were analyzed in mouse peritoneal macrophages of wild-type (WT), Abcd1-deficient (Abcd1 KO), Abcd2-deficient (Abcd2 KO) and Abcd1/Abcd2 double-deficient (DOKO) mice after 5 days in culture (n = 3). The graphs indicate geometric means ± SD (asymmetrical). Statistically significant differences are indicated: * p<0.05, ** p<0.01, *** p<0.001; n.s., no statistically significant difference.
Figure 3 VLCFA levels in wild-type, Abcd1 and Abcd2 single-deficient and Abcd1/Abcd2 double-deficient mouse peritoneal macrophages. The concentrations of the VLCFA species C26∶0, C24∶0 and C22∶0 and the LCFA C16∶0 were determined by GC-MS. The relative amounts of fatty acids, expressed as ratios: (A) C26∶0/C22∶0; (B) C26∶0/C16∶0; (C) C24∶0/C22∶0 and (D), C22∶0/C16∶0 were analyzed in mouse peritoneal macrophages of wild-type (WT), Abcd1-deficient (Abcd1 KO), Abcd2-deficient (Abcd2 KO) and Abcd1/Abcd2 double-deficient (DOKO) mice after 5 days in culture (n = 3). The graphs indicate geometric means ± SD (asymmetrical). Statistically significant differences are indicated: * p<0.05, ** p<0.01, *** p<0.001; n.s., no statistically significant difference.CC BY · PubMed Central
Figure 4 Elovl1 mRNA levels in wild-type, Abcd1-, Abcd2-, and Abcd1/Abcd2 double-deficient mouse peritoneal macrophages. The Elovl1 mRNA copy numbers were determined by qRT-PCR in total RNA from mouse peritoneal macrophages of wild-type (WT), Abcd1-deficient (Abcd1 KO), Abcd2-deficient (Abcd2 KO) and Abcd1/Abcd2 double-deficient (DOKO) mice. The graphs indicate mean values ± SD after normalization to the level of Hprt mRNA in each sample (n = 3).
Figure 4 Elovl1 mRNA levels in wild-type, Abcd1-, Abcd2-, and Abcd1/Abcd2 double-deficient mouse peritoneal macrophages. The Elovl1 mRNA copy numbers were determined by qRT-PCR in total RNA from mouse peritoneal macrophages of wild-type (WT), Abcd1-deficient (Abcd1 KO), Abcd2-deficient (Abcd2 KO) and Abcd1/Abcd2 double-deficient (DOKO) mice. The graphs indicate mean values ± SD after normalization to the level of Hprt mRNA in each sample (n = 3).CC BY · PubMed Central
Figure 5 β-Oxidation activity for C26∶0 in wild-type, Abcd1-, Abcd2-, and Abcd1/Abcd2 double-deficient mouse peritoneal macrophages. The rates of β-oxidation for radiolabelled C26∶0 and C16∶0 fatty acid substrates were measured in wild-type (WT), Abcd1-deficient (Abcd1 KO), Abcd2-deficient (Abcd2 KO) and Abcd1/Abcd2 double-deficient (DOKO) cell preparations. The results are shown as mean values ± SD of the ratio between C26∶0 and C16∶0. The numbers of samples (n) are indicated below the graphs. Statistically significant differences are indicated; *** p<0.001.
Figure 5 β-Oxidation activity for C26∶0 in wild-type, Abcd1-, Abcd2-, and Abcd1/Abcd2 double-deficient mouse peritoneal macrophages. The rates of β-oxidation for radiolabelled C26∶0 and C16∶0 fatty acid substrates were measured in wild-type (WT), Abcd1-deficient (Abcd1 KO), Abcd2-deficient (Abcd2 KO) and Abcd1/Abcd2 double-deficient (DOKO) cell preparations. The results are shown as mean values ± SD of the ratio between C26∶0 and C16∶0. The numbers of samples (n) are indicated below the graphs. Statistically significant differences are indicated; *** p<0.001.CC BY · PubMed Central

Verification

Claims the paper makes

13 Valid · 1 Not valid · 8 Not checked · 51 Own results and interpretations

39 more claims · 2 with their cited sources checked

Create a free account to see all 73 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 22
  • Probably not a substantial claim. 11

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 67 references

Research works printed but not linked: 1

  1. Van Roermund CW, Ijlst L, Wagemans T, Wanders RJ, Waterham HR (2013) A role for the human peroxisomal half-transporter ABCD3 in the oxidation of dicarboxylic acids. Biochim Biophys Acta. · DOI · Paper page

Cited by

See all 33

Metadata

Authors
Muneer, Z., Wiesinger, C., Voigtländer, T., Werner, H. B., Berger, J., & Forss-Petter, S.
Affiliations
  • Medical University of Vienna (AT)
  • Max Planck Institute of Experimental Medicine (DE)
Venue
PLoS ONE
Published
2014-09-25
Volume
9
Issue
9
Pages
e108655
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2095313254
Cited by
33
References
68
Citations by year
2026: 2 · 2024: 6 · 2023: 5 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 2 · 2018: 2 · 2017: 1 · 2015: 5
FWCI
1.38
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Max Planck Institute for Plasma Physics (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
Funders
  • European Commission (241622, FP7-HEALTH-2009)
  • Austrian Science Fund (P26112, P26112-B19,)
  • Higher Education Commision, Pakistan
  • FP7 Health
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
X-linked adrenoleukodystrophy, ABCD1, ABCD2, very long chain fatty acids, peroxisomal beta-oxidation, peritoneal macrophages, ELOVL1, peroxisomal disorders, genetic modifiers, neuroinflammation
MeSH terms
ATP Binding Cassette Transporter, Subfamily D, ATP Binding Cassette Transporter, Subfamily D, Member 1, Fatty Acid Elongases, Long-Chain-Fatty-Acid-CoA Ligase, Acetyltransferases, Animals, Coenzyme A Ligases, Fatty Acids, Gene Expression Regulation, Genetic Vectors, Male, Oxidation-Reduction, RNA, Messenger, Macrophages, Peritoneal, Mice, Knockout, Gene Targeting, ATP-Binding Cassette Transporters, Peroxisomes, Gene Silencing, Gene Order, Lipid Metabolism, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Abcd2 Is a Strong Modifier of the Metabolic Impairments in Peritoneal Macrophages of Abcd1-Deficient Mice. https://app.cochat.ai/papers/10.1371/journal.pone.0108655
The paper
Muneer, Z., Wiesinger, C., Voigtländer, T., Werner, H. B., Berger, J., & Forss-Petter, S. (2014). Abcd2 Is a Strong Modifier of the Metabolic Impairments in Peritoneal Macrophages of Abcd1-Deficient Mice. PLoS ONE. https://doi.org/10.1371/journal.pone.0108655

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.